Amid the rising tide of regenerative medicine, stem cell technology is reshaping the medical landscape at an unprecedented pace. To systematically empower industry development, the Shanghai Stem Cell Clinical Translation Research Institute, in collaboration with over 20 authoritative institutions across China, has dedicated months to compiling the "Clinical-Grade Stem Cell Biobank Development Blue Book". This comprehensive blueprint integrates policy insights, technical standards, academic advancements, and industry trends, charting a clear course for the construction of stem cell biobanks and industrial progression.

      Three distinguished experts from Zhejiang Tianyuan Biotechnology Co., Ltd.—Dr. Liu Guangcheng, Dr. Chen Junjie, and Dr. Hu Yongwu—played pivotal roles in this initiative. Leveraging their profound academic expertise and extensive practical experience, they meticulously refined the content of the Blue Book, establishing it as a scientific, forward-looking, and practical authoritative guide for the industry.

      The release of the "Clinical-Grade Stem Cell Biobank Development Blue Book" coincides with a critical juncture in the maturation of the stem cell industry. Domestically, it accurately interprets regulatory trends, dissects policy incentives and compliance requirements for biobank construction across regions, and safeguards compliant industry operations. Simultaneously, it addresses key industry challenges by proposing standardized, intelligent, and internationalized solutions, offering a clear roadmap for translating stem cells from laboratory "samples" into clinical "therapies", thereby driving the high-quality development of regenerative medicine from all dimensions.

      Zhejiang Tianyuan Biotechnology Co., Ltd. has consistently adhered to a development philosophy of open collaboration and innovation leadership. Its deep involvement in the compilation of the Blue Book once again demonstrates its industry responsibility and technical prowess. Moving forward, Tianyuan Bio will continue to collaborate with all stakeholders, using technological innovation as the sail and expert wisdom as the helm, navigating the stem cell industry toward broader horizons and pioneering new pathways for global health.

      Zhejiang Tianyuan Biotechnology Co., Ltd., founded in 2017, is a national high-tech enterprise dedicated to cell research, development, production, operation, and service. It possesses valuable resource banks including an HLA Umbilical Cord Matching Library, iPS Seed Cell Bank, and Cancer Cell Bank. The company is the drafting unit for the National Health Commission's association standard on immune function assessment methods. In collaboration with the National Health Commission's Research Institute, it has co-established a Joint Laboratory for Metabolic Immunity Monitoring. Furthermore, it serves as important research and service platforms, including the Ningbo Storage Center of the National Stem Cell Transformation Resource Bank and the Achievement Transformation Center of the National Health Commission's Research Institute.